Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2009 plus antitumor therapy in advanced solid tumors
CTR20233099Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ruzaltatug rezetecan in non-small cell lung cancer (NSCLC), Nonhematologic neoplasms, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Nov 2023; status: active.
02
Drugs
ruzaltatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20233099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233099.